Organisation paid for research Program year 2024 Source: CMS Open Payments

Abrh LLC

Neither a doctor nor a teaching hospital

Research payments

$5,332,017

666 payments

Through program year 2024, Abrh LLC is reported as receiving $5,332,017 in research payments, across 666 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$8,032	4
2022	Research	$18,208	6
2021	Research	$16,429	5
2020	Research	$738,676	161
2019	Research	$4,550,672	490

Breakdown

Who paid Research payments · program years 2019–2024

GlaxoSmithKline, LLC. $2,648,281 286 payments
AstraZeneca Pharmaceuticals LP $1,293,080 71 payments
Cipla USA Inc. $507,788 74 payments
AstraZeneca AB $273,738 7 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $197,365 10 payments
Sanofi US Services Inc. $164,620 89 payments
AbbVie, Inc. $77,792 54 payments
LEO Pharma AS $69,896 24 payments
Bayer HealthCare Pharmaceuticals Inc. $25,589 31 payments
Mylan Specialty L.P. $22,636 2 payments

Studies the money was for Research payments · program years 2019–2024

A Phase IV, 12 Week, Randomised, Double Blind Study to Compare Single $874,638 79 payments
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $737,910 38 payments
A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $615,371 33 payments
A Randomized, Double-Blind (Sponsor Unblind), Placebo-Controlled Study $463,584 25 payments
U-Fs-Mu-As3120 $458,950 60 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $403,526 17 payments
A Phase IV, 12 Week, Randomised, Double-Blind, Double-Dummy Study to C $374,343 69 payments
A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS $270,330 4 payments
Tio & Olo versus PBO stratified by PIFR $188,965 3 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $117,753 73 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.